Comparison of Transcutaneous Vs End-tidal CO2 Pressure Measurements in Hyperventilation Syndrome Diagnosis

Overview

Hyper Ventilation Syndrome is a frequent disease affecting adults whose diagnosis is often belated or even unrecognized due to the lack of "gold standard" criteria. Its diagnosis currently relies on the Nijmegen score associated with a PetCO2 assesment using a hyperventilation provocation test. Correlation between Nijmegen Questionnaire scores and PetCO2 appears highly variable. PtcCO2 monitoring is a noninvasive alternative method providing a continuous estimation of arterial CO2 pressure (PaCO2) which could represent an advantageous alternative to PetCO2 measurements. Several reports have demonstrated that PtcCO2 monitoring reflects more faithfully PaCO2 than PetCO2, no study have evaluated its value in this indication. The primary aim of the study is to compare the diagnostic value of PtcPCO2 monitoring with PetCO2, the method currently used. Included patient will be invited to fill in the Nijmegen questionnaire and an ambient air gas measurement will be performed. PtcCO2 (mmHg) will be simultaneously measured during hyperventilation test. Nijmegen score signs reproduced by the test will be analysed. HVS diagnosis will be assessed by usual criteria (PetCO2 <30 mmHg at the end of hyperventilation test or under the PetCO2 value at rest, Nijmegen score> 23). PtcCO2 data will be blinded interpreted later. We will compare if PetCO2 and PtcCO2 leads to the same diagnosis or not.

Full Title of Study: “Transcutaneous Carbon Dioxide Pressure (tcPCO2) Monitoring Vs End-tidal Partial Pressure Carbon Dioxide (PetCO2) Measurement in the Diagnosis of Hyperventilation Syndrome (HVS) (TCvsPETCO2 )”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Diagnostic
    • Masking: None (Open Label)
  • Study Primary Completion Date: February 15, 2018

Detailed Description

Primary Goal: Show that the use of either of the two pCO2 measurements leads to the same diagnostic conclusion in HVS diagnosis with a likelihood greater than 80 %. Secondary Outcome Measures : Evaluate the correlation between PtcCO2 and PtcCO2 measurements Evaluate tolerance to the hyperventilation test Inclusion Criteria : 1. The patient must have reached the age of the civil majority (≥ 18 yo) 2. All patients refered to the Physiology department of Rouen University Hospital, France, for an hyperventilation test 3. The patient must be a member or beneficiary of a health insurance program 4. The patient must have given his / her free and informed consent and signed the consent Exclusion Criteria : 1. Sepsis 2. Hypercapnia (PaCO2 > 50mmHg) 3. Patient treated by long-term oxygen therapy 4. Subjects under judicial protection, or adults under any kind of guardianship or under judicial control 5. Pregnancy or breastfeeding women 6. Electrolytic unbalance 7. Hyperthyroidism 8. Neurological disease 9. Probability of drug-induced hyperventilation (progestagens , aspirin, beta agonists)

Interventions

  • Diagnostic Test: Simultaneous Transcutaneous and End-tidal CO2 measurements
    • Included patients will be invited to fill in the Nijmegen questionnaire. During the hyperventilation test, PtcCO2 (mmHg) will be recorded simultaneously with the standard End-tidal Cpartial pressure CO2 measurement

Arms, Groups and Cohorts

  • Experimental: Patients tested for hyperventilation
    • Simultaneous Transcutaneous and End-tidal CO2 measurements. Eligible patients will be first invited to fill in the Nijmegen questionnaire. Then, in an hyperventilation test, transcutaneous Carbon Dioxide Pressure will be recorded simultaneously with the standard End-tidal Carbon Dioxide Pressure measurement.

Clinical Trial Outcome Measures

Primary Measures

  • Trans-cutaneous Carbon Dioxide pressure
    • Time Frame: during hyperventilation test
    • Trans-cutaneous Carbon Dioxide pressure measurements diagnostic of hyperventilation syndrome will be evaluated by comparing it with that of standard
  • End-tidal Carbon Dioxide partial pressure
    • Time Frame: during hyperventilation test
    • End-tidal Carbon Dioxide partial pressure measurement. Consistency of the diagnostic conclusions reached by either test will be analyzed.

Participating in This Clinical Trial

Inclusion Criteria

1. The patient must have reached the age of the civil majority (≥ 18 yo) 2. All patients refered to the Physiology department of Rouen University Hospital, France, for an hyperventilation test 3. The patient must be a member or beneficiary of a health insurance program 4. The patient must have given his / her free and informed consent and signed the consent Exclusion Criteria:

1. Sepsis 2. Hypercapnia (PaCO2 > 50mmHg) 3. Patient treated by long-term oxygen therapy 4. Subjects under judicial protection, or adults under any kind of guardianship or under judicial control 5. Pregnancy or breastfeeding women 6. Electrolytic unbalance 7. Hyperthyroidism 8. Neurological disease 9. Probability of drug-induced hyperventilation (progestagens , aspirin, beta agonists)

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University Hospital, Rouen
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • ARTAUD-MACARI Elise, MD, Principal Investigator, Rouen University Hospital

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.